Top Markets
#1 PulseChain PulseChain +45.01%
#2 MarsCoin MarsCoin +17.39%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.92%
#4 RedStone RedStone +15.11%
#5 Bitway Bitway +11.33%
#6 Meteora Meteora +9.28%
#7 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +8.13%
#8 Lighter Lighter +8.05%
#9 SkyAI SkyAI +7.96%
#10 OPENLOOT OPENLOOT +7.58%
Coin of the day
PulseChain PulseChain
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Classifica tra le azioni #28046
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Prezzo delle azioni
$0.55
Ultima sincronizzazione: 2025-02-11
Capitalizzazione di mercato
$28.90M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Marinus Pharmaceuticals, Inc. (MRNS)

Categoria

Healthcare
Rapporto P/B per Marinus Pharmaceuticals, Inc. (MRNS)
Rapporto P/B al August 2026 TTM: 1.76
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Marinus Pharmaceuticals, Inc., il rapporto P/B attuale (TTM) è 1.76. Alla fine del 2022, era pari a 0.34.
Storico del rapporto P/B per Marinus Pharmaceuticals, Inc. da 2012 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
2026 (TTM) 1.76 -79.78%
2023 8.72 2,502.21%
2022 0.34 -83.55%
2021 2.04 236.14%
2020 0.61 80.74%
2019 0.34 -21.91%
2018 0.43 -48.12%
2017 0.83 261.21%
2016 0.23 -62.26%
2015 0.61 53.71%
2014 0.40 -76.83%
2013 1.71 -55.78%
2012 3.86 0.00%
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 259.68%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 110.34%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 253.98%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 42.09%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH